CanSino Biologics Inc. (HKG:6185)
29.34
-1.06 (-3.49%)
May 12, 2026, 4:08 PM HKT
CanSino Biologics Revenue
CanSino Biologics had revenue of 190.28M CNY in the quarter ending March 31, 2026, with 38.73% growth. This brings the company's revenue in the last twelve months to 1.12B, up 28.97% year-over-year. In the year 2025, CanSino Biologics had annual revenue of 1.07B with 26.18% growth.
Revenue (ttm)
1.12B CNY
Revenue Growth
+28.97%
P/S Ratio
10.17
Revenue / Employee
988.56K CNY
Employees
1,134
Market Cap
12.95B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.07B | 221.57M | 26.18% |
| Dec 31, 2024 | 846.34M | 489.25M | 137.01% |
| Dec 31, 2023 | 357.08M | -677.51M | -65.49% |
| Dec 31, 2022 | 1.03B | -3.27B | -75.94% |
| Dec 31, 2021 | 4.30B | 4.27B | 17,174.82% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Revenue RankingsCanSino Biologics News
- 3 months ago - CanSinoBIO at WGS 2026: Accelerating Global Access to Innovative Vaccines - PRNewsWire
- 3 years ago - World-First Inhaled COVID-19 Vaccine, Developed in Partnership Between Aerogen® and CanSinoBIO, First Public Booster Immunization in China. - Business Wire
- 4 years ago - China's CanSinoBIO H1 revenue drops on weaker COVID shot demand - Reuters
- 4 years ago - CanSinoBIO's COVID-19 Vaccine Convidecia™ Receives WHO Emergency Use Listing - PRNewsWire
- 4 years ago - CanSinoBIO Rebrands to Reflect Commitment to Life Sciences Research - PRNewsWire
- 4 years ago - CanSinoBIO's COVID-19 mRNA Vaccine Receives Approval of Clinical Trial Application in China - PRNewsWire
- 4 years ago - CanSinoBIO's Convidecia™ Approved as Heterologous Booster in Malaysia and Indonesia - PRNewsWire
- 4 years ago - Latest Study Shows Advantages of CanSinoBIO's Convidecia™ as Heterologous Booster against Omicron Variant - PRNewsWire